ARS Pharmaceuticals (SPRY) Operating Leases (2020 - 2025)

ARS Pharmaceuticals (SPRY) posted Operating Leases of $949000.0 for Q3 2025, down 11.47% sequentially from $1.1 million in Q2 2025.

ARS Pharmaceuticals (SPRY) Operating Leases (2020 - 2025) Analysis & Trends

ARS Pharmaceuticals has reported Operating Leases for 5 years, with the latest figure at $949000.0 in Q3 2025.

Quarterly Operating Leases changed N/A year-over-year to $949000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $949000.0 (changed N/A YoY) and the FY2023 annual result came in at $37000.0, down 85.26% from the prior year.
Operating Leases eased to $949000.0 in Q3 2025 per SPRY's latest filing, from $1.1 million in the prior quarter.
Over five years, Operating Leases peaked at $5.1 million in Q3 2021 and troughed at $37000.0 in Q4 2023.
A 4-year average of $1.7 million and a median of $949000.0 in 2025 frame the typical range for Operating Leases.
The sharpest annual moves came in 2022 and 2023: Operating Leases surged 128.63% in 2022, then sank 96.41% in 2023.
Over 4 years, Operating Leases stood at $480000.0 in 2021, then sank by 47.71% to $251000.0 in 2022, then sank by 85.26% to $37000.0 in 2023, then soared by 2464.86% to $949000.0 in 2025.
According to Business Quant data, Operating Leases over the past three periods registered $949000.0, $1.1 million, and $37000.0 for Q3 2025, Q2 2025, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	ARS Pharmaceuticals	561.88 Mn	418.03 Mn	-

Download Data